about
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMTThe Natural Antiangiogenic Compound AD0157 Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells.Branched-chain amino acid metabolism in cancer.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis.Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.Protein kinase inhibitors for acute leukemia.Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways.A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AMLSRSF2 mutations in myelodysplasia/myeloproliferative neoplasmsAcute Myeloid Leukemia: Is That All There Is?Molecular landscape and targeted therapy of acute myeloid leukemia
P2860
Q33820379-E49C09FC-FD1C-457F-9130-29A804BE5660Q45383909-74234E6A-C807-48F1-85C5-0F9A1E47BDE0Q46301158-C06BC0A0-4D7A-46A4-98E8-15F7CC056D81Q47136441-1A52E727-E86D-464A-93BF-9FFCCF9D0977Q47221234-1EFE1405-CD9F-40B6-9168-BE08E54AE848Q47747424-5BA931F9-E939-4108-9B30-ADF6D7938662Q47865655-35A7EF6E-8CFF-4C17-9850-364EADB78ACEQ48267407-15D22F17-F3FC-4E3F-BC8D-3923F30B7A80Q49168672-B1188871-8C1E-4C2D-AB16-7D4CC7D3B556Q49873905-82A33EAB-17CF-402C-BB0C-57509F72C9FFQ49957074-C91D2AE2-FEDD-42B5-B10F-C092752F5E7BQ52668830-2CA7877F-A014-4A94-BA17-92F68D2651F8Q57039806-BFA615F7-9356-4D9D-B902-5CE0161B202DQ57069030-33C59100-3FFF-47DA-96FE-6D5A7EECFC62Q58564462-C99DC99C-AF56-44F2-AEC6-8EA387C5F1A1Q59130314-1F746042-AB3C-4ABF-94A4-27C673BC0E02
P2860
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Emerging therapies for acute myeloid leukemia.
@ast
Emerging therapies for acute myeloid leukemia.
@en
Emerging therapies for acute myeloid leukemia.
@nl
type
label
Emerging therapies for acute myeloid leukemia.
@ast
Emerging therapies for acute myeloid leukemia.
@en
Emerging therapies for acute myeloid leukemia.
@nl
prefLabel
Emerging therapies for acute myeloid leukemia.
@ast
Emerging therapies for acute myeloid leukemia.
@en
Emerging therapies for acute myeloid leukemia.
@nl
P2860
P1476
Emerging therapies for acute myeloid leukemia.
@en
P2093
Caner Saygin
Hetty E Carraway
P2860
P2888
P356
10.1186/S13045-017-0463-6
P5008
P577
2017-04-18T00:00:00Z
P6179
1084930903